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of up to 112µm. Histological features of the subchondral bone
resorption pits were analysed with H&E staining. Tartrate resis-
tant acid phosphatase (TRAP) positive cells were identiﬁed by
immunohistochemsitry. Normal cartilage and subchondral bone
were obtained from femoral heads at post mortem from cadavers
with no clinical history of OA (n = 9).
Results: Resorption pits were divided into ﬁve groups which
were classiﬁed by morphological phenotype based on the con-
tent of cells present within the pit and the location of the pit within
the subchondral/calciﬁed cartilage space. All resorption pits ex-
amined contained TRAP positive osteoclast-like cells indicating
the destructive nature of these lesions. The concurrent presence
of osteoblasts and osteoclasts within the resorption pits suggests
the involvement of the resorption pits in the process of bone
remodelling and possibly sclerosis. Histological analysis of sam-
ples suggested that resorption pits may arise from the normal
pit structure that is seen within the subchondral plate and may
extend through a process of bone resorption and remodelling,
to involve a larger area of the subchondral region and encroach
on overlying calciﬁed and articular cartilage. 3D reconstruction
of subchondral bone resorption pits demonstrated a branching
morphology with smaller pits interlinking with a larger resorption
pit which linked with bone marrow. This branching morphology
suggesting possible development of resorption pits through pre-
existing vascular channels or the interaction of bridging areas of
bone resorption.
Conclusions: Subchondral bone resorption pits can be classi-
ﬁed into various types based on their morphology; these separate
classiﬁcations may represent a development sequence from fo-
cal (normal) areas of endochondral ossiﬁcation or expansion of
bone vascular channels. The extensive nature of these lesions
may also be a reﬂection of altered biomechanical stresses on the
subchondral plate and may, in turn, contribute to altered bone
responses and joint instability in OA.
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Purpose: Transforming growth factor-β (TGF-β) is a multifunc-
tional regulator of chondrocyte proliferation, differentiation and
extracellular matrix production. Dysregulation of TGF-β action
has been implicated in cartilage diseases such as osteoarthritis.
TGF-β signaling is transduced through a pair of transmembrane
serine/threonine kinases, known as the type I (ALK5) and type
II (TβRII) receptors. Activation of ALK5 leads to phosphoryla-
tion of intracellular Smad2 and Smad3, which associate with
the common Smad4 and then translocate to the nucleus where
they interact with coactivators and/or corepressors to modulate
expression of target genes in a cell-speciﬁc manner. However,
recent studies on endothelial cells have identiﬁed another TGF-β
type I receptor named ALK1, and its activation does not lead
to phosphorylation of Smad2 or Smad3, but instead leads to
phosphorylation of Smad1, 5 and 8. The goal of this study
was to determine if ALK1 is expressed in human chondrocytes
and to characterize its role in regulation of TGF-β signaling and
responses in human chondrocytes.
Methods: ALK1 mRNA and protein expression in human chon-
drocytes were examined by RT-PCR and Western blotting. The
interaction of ALK1 with other TGF-β receptor components was
studies by (1) [125I]TGF-β1 afﬁnity labeling of cell surface recep-
tors followed by immunoprecipitation with TGF-β receptor spe-
ciﬁc antibodies and (2) immunoprecipitation of unlabeled TGF-β
receptors followed by Western blotting using an anti-HA anti-
body to detect exogenously expressed ALK1-HA. The functional
role of ALK1 in regulation of TGF-β1-induced signaling and re-
sponses was examined by gain and loss of function studies.
Human chondrocytes overexpressing ALK1 or in which endoge-
nous ALK1 levels were reduced by ALK1 siRNA knockdown
were examined for their responsiveness to TGF-β1 by measuring
transcriptional activity (3TP-lux), Smad3-speciﬁc transcriptional
activity (CAGA12-lux), Smad1/5 and Smad3 phosphorylation and
expression levels of extracellular matrix components (type II
collagen, PAI-1 and ﬁbronectin).
Results: ALK1 mRNA and protein expression were demon-
strated in human chondrocytes. ALK1 was shown to be a com-
ponent of the TGF-β receptor system in human chondrocytes,
as evidenced by its interaction with ALK5, TβRII, endoglin and
betaglycan in the presence or absence of TGF-β1 ligand. Our
results indicate that both ALK1 and ALK5 are required for TGF-
β-induced phosphorylation of Smad1/5 whereas only ALK5 is
essential for TGF-β1-induced phosphorylation of Smad3 in these
cells. In addition, our results demonstrate that ALK1 inhibits,
while ALK5 potentiates, TGF-β-induced Smad3-driven transcrip-
tional activity and the expression of PAI-1, ﬁbronectin and type II
collagen.
Conclusions: Our results suggest that, in human chondrocytes,
TGF-β signals through two TGF-β type I receptors: ALK1 and
ALK5. Activation of the ALK5 pathway leads to activation of the
Smad3 pathway and increased expression of extracellular matrix
components, PAI-1, ﬁbronectin and type II collagen, whereas
activation of the ALK1 pathway opposes these functions. Our
study suggests that ALK1 plays an essential role in the regulation
of TGF-β signaling and function in the human cartilage.
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Purpose: The serine protease HtrA1 (also referred to as
PRSS11) has been shown to be one of the most abundant
proteases in cartilage, wherein its levels are upregulated during
osteoarthritis (OA). A hexapeptide derived from the C-terminus
of procollagen type II (and type III), designated CPII, has previ-
ously been shown to stimulate HtrA1 protease activity by tightly
interacting with its PDZ domain. The purpose of this study was
to investigate HtrA1-mediated cleavage of aggrecan and the ag-
onistic effect of CPII on HtrA1 activity, and to better understand
the role of HtrA1 in OA disease progression.
Methods: Identiﬁcation of potential HtrA1 substrates: Wildtype
HtrA1 (amino acids 157-480) and an inactive HtrA1 mutant
(S328A) were overexpressed in 3-D alginate cultures of primary
human chondrocytes. A mass spectrometry-based method was
utilized to identify potential HtrA1-generated cleavage products
released into the culture medium. In vitro cleavage of aggrecan:
Puriﬁed human aggrecan and recombinant aggrecan constructs
comprising either the G1-interglobular domain (IGD)-G2 or IGD
alone were incubated with puriﬁed recombinant HtrA1 (aa 157-
480) or an inactive HtrA1 mutant (aa 157-480, S328A). A control
peptide or CPII was added to the reactions to evaluate potential
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agonistic effects. The reaction products were separated by SDS-
PAGE, followed by Coomassie Blue or silver staining. Treatment
of cartilage explants with HtrA1: Human osteoarthritic cartilage
explants were treated with recombinant HtrA1, with or without
CPII. Conditioned media were assayed for sGAG release by
DMMB. Proteoglycans in the media were precipitated using 1%
cetylpyridinium chloride and subjected to SDS-PAGE followed by
Coomassie Blue or silver staining.
Results: The cartilage proteoglycan aggrecan was identiﬁed
as one of the potential substrates of HtrA1 in the mass
spectrometry-based “degradomics” analysis. Incubation of re-
combinant aggrecan G1-IGD-G2 and IGD constructs with wild-
type HtrA1, but not mutant HtrA1, resulted in distinct cleavage
of these substrates. HtrA1 activity was further enhanced by the
peptide agonist CPII, and inhibited by the HtrA inhibitor Ucf-101.
In addition, recombinant HtrA1 cleaved native human aggrecan in
the presence of the CPII peptide agonist. Treatment of cartilage
explants with recombinant HtrA1 signiﬁcantly increased (p<0.05)
the amount of sGAG released compared to control. Further, the
addition of CPII signiﬁcantly increased (p<0.05) the amount of
sGAG release compared to treatment with HtrA1 alone.
Conclusions: Our data suggest that the collagen type II C-
propeptide may induce proteoglycan catabolism by stimulating
the protease activity of HtrA1. Elevated levels of collagen type
II C-propeptide have been detected in osteoarthritic human ar-
ticular cartilage, due to increased collagen synthesis. Excessive
HtrA1 protease activity in OA cartilage may represent another
contributing factor in OA disease progression.
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CRUCIAL ROLE OF VISFATIN/PBEF IN MATRIX
DEGRADATION AND PGE2 SYNTHESIS IN
CHONDROCYTES: POSSIBLE INFLUENCE ON
OSTEOARTHRITIS
M. Gosset1, F. Benrenbaum2, C. Salvat1, A. Sautet3,
A. Pigenet1, M. Holzenberger4, C. Jacques1
1UMR 7079 CNRS/Paris VI, Paris, France; 2UMR 7079
CNRS/Paris VI/Department of Rheumatology, Saint Antoine
Hospital, Paris, France; 3UFR Paris VI, Department of
Orthopaedics, Saint Antoine Hospital, Paris, France; 4Inserm
515, Paris, France
Purpose: To evaluate the contribution of visfatin, an adipose
tissue-derived hormone, to the pathophysiology of osteoarthritis
(OA) by examining its role in prostaglandin E2 (PGE2) synthe-
sis and matrix degradation. In an inﬂammatory context, PGE2
synthesis is catalysed by cyclooxygenase type 2 (COX-2) and mi-
crosomal prostaglandin E synthase type 1 (mPGES-1), whereas
NAD+-dependent 15-hydroxy prostaglandin dehydrogenase (15-
PGDH) degrades PGE2.
Methods: The synthesis of visfatin by human chondrocytes
from OA patients, with and without stimulation with interleukin-
1β (IL-1β- 10 ng/ml), was assessed by real-time RT-PCR and
immunoblotting. The effects of visfatin (1 to 10µg/ml) on mPGES-
1, 15-PGDH, PGE2, MMP-3 and MMP-13 expressions by human
OA chondrocytes and by primary mouse articular chondrocytes
were examined by quantitative RT-PCR, immunoblotting and
ELISA. A siRNA strategy was used to assess the inﬂuence
of visfatin on the IL-1β induced release of PGE2. Finally, the
role of IGF-1R in visfatin signalling was studied using primary
chondrocytes from IGF-1R knockout mice (IGF-1R-/-).
Results: (1) Visfatin was constitutively expressed by cultured
human OA chondrocytes. Its expression increased 6-fold in re-
sponse to 10 ng/ml IL-1β (p<0.05).
(2) Visfatin at 1 to 5 µg/ml triggered MMP-3 and MMP-13
mRNA expression (up to 6-fold, p<0.01) by primary mouse
articular chondrocytes. Stimulation with 5 µg/ml visfatin led to a
release of 572 ± 280 ng/ml MMP-3 protein (p<0.05). Visfatin
also induced i) PGE2 release (controls 47 ± 8 versus 141 ± 10
pg/ml when treated with 10 µg/ml visfatin, p<0.05), ii increased
expression of the mPGES-1 (14-fold increase, p<0.01) and iii) a
90% decrease (p<0.05) of the 15-PGDH. Interestingly, 1 ng/ml
IL-1β plus visfatin (1, 2.5 or 5 µg/ml for 24 hours) had additive
effects on PGE2 release (19-fold, 31-fold and 35-fold compared
to IL-β, p<0.05; [1 ng/ml IL-β released 1506 ± 67 pg/ml]).
Moreover, IL-1β dramatically decreased 15-PGDH expression by
95% (p<0.001).
(3) Blocking visfatin expression by siRNA inhibited IL-1β-induced
PGE2 release: triggered the release of (1430 ± 467 pg/ml in
presence of IL-1β (10ng/ml) versus 985 ± 292 pg/ml in presence
of IL-1β + siRNA visfatin, -35%, p<0.01) probably due to a 40%
inhibition of mPGES-1 expression (p<0.01). (4) Visfatin is known
to bind to, and to activate insulin receptor (IR). However, IR is not
considered to be usually present on chondrocytes. We therefore
tested the implication of IGF-1R, a close homologue to IR, in
visfatin signalling. When stimulated with 5 µg/ml visfatin, IGF-
1R-/- chondrocytes unexpectedly exhibited higher PGE2 release
than IGF1R+/+ controls (228 ± 4 compared to 86 ± 29 pg/ml,
p<0.05) which rules out the direct implication of IGF-1R in visfatin
action.
Conclusions: Visfatin triggers the synthesis and the release of
MMP-3 and MMP-13 and induces PGE2 synthesis resulting from
an increase of mPGES-1 and a decrease of 15-PGDH expression
in chondrocytes. We therefore consider that visfatin is a novel
and a potential critical target for OA. In vivo experiments are now
needed to test this hypothesis.
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Purpose: Previous studies (Arthritis Rheum 52:3110-24) showed
that DNA de-methylation at speciﬁc CpG sites in the promoters
was associated with the abnormal synthesis of matrix-degrading
enzymes in human osteoarthritis. However, it is not known
whether DNA de-methylation actually causes the abnormal ex-
pression of the proteases. To demonstrate possible cause-effect
relationships and to study the mechanisms involved in the loss of
DNA methylation requires an in vitro system in which experimen-
tally induced gene induction is correlated with de-methylation at
speciﬁc CpG sites.
Methods: Since monolayer cultures of articular chondrocytes
are an established model to study the induction of the typical
OA proteases by inﬂammatory cytokines, we used this sys-
tem. Healthy chondrocytes were harvested from human femoral
head cartilage after hemi-arthroplasty following a fracture of the
neck of femur. The chondrocytes from each patient were di-
vided into ﬁve groups: non-culture; control culture; culture with
the de-methylating agent 5-aza-deoxycytidine (5-aza-dC) or the
inﬂammatory cytokines IL-1β or TNF-α/oncostatin M. At conﬂu-
ency (4-5 weeks), total RNA and genomic DNA were extracted
simultaneously. Relative mRNA expression was quantiﬁed by
SybrGreen-based real-time PCR and a method for quantifying
the percent of cells with DNA methylation at one speciﬁc CpG
site was developed (Epigenetics 2: 86-95). ELISA was used to
analyze IL-1β in the culture.
Results: Initial non-quantitative experiments conﬁrmed IL-1β -
induced expression of MMP-3 and MMP-13 and also demon-
strated induction of IL-1β by itself, which correlated with loss of
